
Lyophilization may be considered a relatively gentle drying process, but there are still risks and pitfalls when applying it to biomolecular reagents in diagnostic tests that are different to the freeze-drying of general pharmaceuticals. Reagents typically used in ELISA and PCR based diagnostic kits for diseases, such as COVID-19 tend to contain labile components, such as enzymes that need preserving for longevity in the supply chain or antibodies to test for a patient’s response to the virus, which can be challenging to stabilize for commercial use.
This webinar explores various aspects of formulation and cycle development for diagnostic reagents relevant to COVID-19, including the design/selection of container-closure systems and the selection of appropriate equipment.
Please find the link of webinar below:
Please feel free to contact us for more details.
Leave a Comment